Leerink Partners Maintains Outperform on Abivax, Raises Price Target to $148
Leerink Partners analyst Thomas Smith maintains Abivax (NASDAQ: ABVX ) with a Outperform and raises the price target from $140 to $148.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.